Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.

[1]  J. Panés,et al.  Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. , 2006, Gastroenterology.

[2]  A. Torres,et al.  Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. , 2006, Chest.

[3]  K. McColl,et al.  Review article: proton pump inhibitors and bacterial overgrowth , 2006, Alimentary pharmacology & therapeutics.

[4]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[5]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[6]  T. Shimatani,et al.  Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression , 2004, Alimentary pharmacology & therapeutics.

[7]  W. Graninger,et al.  Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity* , 2002, Critical care medicine.

[8]  W. Bilker,et al.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease , 2002, Pharmacoepidemiology and drug safety.

[9]  Hatlebakk,et al.  Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazole , 2000, Alimentary pharmacology & therapeutics.

[10]  Walsh,et al.  Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[11]  Y. Naito,et al.  A new mechanism for anti‐inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil–endothelial cell interactions , 2000, Alimentary pharmacology & therapeutics.

[12]  N. Maekawa,et al.  The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. , 1999, Anesthesia and analgesia.

[13]  J. Panés,et al.  Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. , 1998, Gastroenterology.

[14]  S. Gutthann,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[15]  A. Ruigómez,et al.  Gastric Acid, Acid‐Suppressing Drugs, and Bacterial Gastroenteritis: How Much of a Risk? , 1997, Epidemiology.

[16]  R. Hunt,et al.  The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. , 1997, Clinical therapeutics.

[17]  A. Blum,et al.  Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. , 1996, Gut.

[18]  R. Slack,et al.  Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study , 1996, BMJ.

[19]  J. Persson,et al.  Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers). , 1997, Digestion.

[20]  J. Hollowell,et al.  The General Practice Research Database: quality of morbidity data. , 1997, Population trends.

[21]  M. Hill.  Normal and pathological microbial flora of the upper gastrointestinal tract. , 1985, Scandinavian journal of gastroenterology. Supplement.